- New SMCxPRO(TM) technology offers high speed, high sensitivity for single molecule detection
- Meets customer demand for biomarker and novel target discovery and detection
DARMSTADT, Germany, April 3, 2017 /PRNewswire/ -- Merck [http://www.merckgroup.com/en/index.html], a leading science and technology company, today announced the launch of its newest high-sensitivity detection platform, SMCxPRO(TM) technology, at the American Association for Cancer Research Annual Meeting in Washington, D.C.
Photo - https://mma.prnewswire.com/media/485409/Merck_SMCxPRO.jpg [https://mma.prnewswire.com/media/485409/Merck_SMCxPRO.jpg]
The SMCxPRO(TM) platform allows researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design.
It will be available in Q3 of 2017.
"Merck's newest innovation, SMCxPRO(TM) technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity," said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation at the life science business sector of Merck [http://www.merckgroup.com/en/products/life_science/life_science.html]. "Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare."
Along with the new SMCxPRO(TM) technology, Merck offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company's suite of gene editing tools.
AACR attendees are encouraged to visit booth #931 to learn more about Merck's life science products and to speak with company experts. Follow us on twitter @Merck_lifesci [https://twitter.com/Merck_lifesci].
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe [http://www.merckgroup.com/subscribe] to register online, change your selection or discontinue this service.
About MerckMerck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR 15.0 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merck-introduces-next-generation-high-sensitivity-protein-detection-platform-300433140.html [http://www.prnewswire.com/news-releases/merck-introduces-next-generation-high-sensitivity-protein-detection-platform-300433140.html]
CONTACT: Karen Tiano +49 6151 72 44461